US FDA Accepts Lupins SNDA For Solosec To Treat Trichomoniasis

Lupin Pharmaceuticals, Inc., the US based wholly-owned subsidiary of Lupin Limited (Lupin), announced that the US Food and Drug Administration (FDA) has accepted their supplemental new drug application (sNDA) for Solosec (secnidazole) for the treatment of trichomoniasis in adults and adolescents.The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021.Trichomoniasis vaginalis is the most common non-viral, curable sexually transmitted infection (STI) in the US, affecting an estimated 3 to 5 million people. Solosec 2 g oral granules is currently FDA-approved to treat bacterial vaginosis (BV) in adult women."The FDA acceptance of our application for Solosec to treat trichomoniasis is an important milestone for our company and for patients who are in need of new options for the treatment of trichomoniasis," said Jon Stelzmiller, president – specialty, Lupin Pharmaceuticals, Inc. "We look forward to working with the FDA during their review of our file for this new indication."If approved for trichomoniasis, Solosec could be the only single-dose oral prescription treatment for both BV and trichomoniasis.The Solosec sNDA is based, in part, on trial results that showed a clinically and statistically significant response rate, or microbiological cure, in patients treated with Solosec as compared to placebo (p<0.001). In the per-protocol population, the cure rate was 94.9% (56/59) for Solosec versus 1.7% (1/60) for placebo (p<0.001). Solosec was generally well-tolerated.The most commonly reported adverse events were vulvovaginal candidiasis (2.7%) and nausea (2.7%). No serious adverse events were observed in the trial. The data were presented at the 2020 Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) Virtual Annual Meeting

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!